Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cells

European Journal of Haematology

Volumn 68, Issue 4, 2002, Pages 210-216

  Aivado, M ^a   Rong, A ^a   Stadler, M ^b   Germing, U ^a   Giagounidis, A ^c   Strupp, C ^a   Novotny, J ^d   Josten, K M ^e   Kobbe, G ^a   Hildebrandt, B ^a   Gattermann, N ^a   Aul, C ^c   Haas, R ^a   Ganser, A ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c ST JOHANNES HOSPITAL   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

Author keywords

Antilymphocyte globulin; Antithymocyte globulin; Clonality; HUMARA; Myelodysplastic syndrome; PGK 1

Indexed keywords

ANDROGEN RECEPTOR; HEMOGLOBIN; LYMPHOCYTE ANTIBODY; PHOSPHOGLYCERATE KINASE; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; ENZYME ASSAY; FEMALE; GRANULOCYTE; HUMAN; HUMAN TISSUE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFRACTORY ANEMIA; REMISSION; RISK FACTOR; T LYMPHOCYTE; THROMBOCYTE COUNT; X CHROMOSOME INACTIVATION;

AGED; ANTILYMPHOCYTE SERUM; BONE MARROW CELLS; CELL DIFFERENTIATION; DOSAGE COMPENSATION, GENETIC; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME;

EID: 20244381363     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2002.01625.x     Document Type: Article

References (26)

1. Clonality of cell populations in refractory anaemia using combined approach of gene loss and X-linked restriction fragment length polymorphism-methylation analyses
2. Refractory anaemia with preleukaemic polyclonal haemopoiesis and the emergence of monoclonal erythropoiesis on disease progression
3. Clonal involvement of granulocytes and monocytes, but not of T and B lymphocytes and natural killer cells in patients with myelodysplasia: Analysis by X-linked restriction fragment length polymorphisms and polymerase chain reaction of the phosphoglycerate kinase gene
4. Lineage specificity in haematological neoplasms
5. Clonal analysis of myelodysplastic syndromes: Evidence of multipotent stem cell origin
6. Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms
7. Clonality in myelodysplastic syndromes: Demonstration of pluripotent stem cell origin using X-linked restriction fragment length polymorphisms
8. Recovery of polyclonal hematopoiesis in patients with myelodysplastic syndromes following successful chemotherapy
9. Evidence for nonclonal hematopoietic progenitor cell populations in bone marrow of patients with myelodysplastic syndromes
10. Quantitative non-radioactive clonality analysis of human leukemic cells and progenitors using the human androgen receptor (AR) gene
11. Clonal analysis of peripheral blood and haemopoietic colonies in patients with aplastic anaemia and refractory anaemia using the polymorphic short tandem repeat on the human androgen-receptor (HUMARA) gene
12. Longitudinal study of clonality in patients with high-risk myelodysplastic syndromes
13. Clinical outcome in three patients with myelodysplastic syndrome showing polyclonal hematopoiesis
14. Antithymocyte globulin for patients with myelodysplastic syndrome
15. Antilymphocyte globulin, cyclosporin A, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): A pilot study of the EBMT SAA Working Party
16. Intensive immunosuppression with antithymocyte globulin and cyclosporin as treatment for severe acquired aplastic anemia
17. Anti-lymphocyte versus anti-thymocyte globulin in low-risk myelodysplastic syndromes: A phase II study
18. Myelodysplastic syndrome and aplastic anemia: Distinct entities or diseases linked by a common pathophysiology?
19. Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity
20. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine
21. Familial skewed X inactivation: A molecular trait associated with high spontaneous-abortion rate maps to Xq28
22. Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated wi h restoration of polyclonal haemopoiesis
23. Langerhans'-cell histiocytosis (histiocytosis X) - A clonal proliferative disease
24. Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age
25. A joint study of the EORTC, EBMT, SAKK, HOVON and G1MEMA leukemia groups. The impact of cytogenetic features and clonality on the prognosis of patients with poor risk MDS and secondary AML treated with intensive chemotherapy and stem cell transplantation
26. Methylation patterns in human androgen receptor gene and clonality analysis